文献速递炎症性肠病

克罗恩病住院与手术干预率下降:基于人群的队列研究

Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-17

该研究基于加拿大安大略省行政数据,纳入45 235例克罗恩病患病患者,评估生物制剂时代疾病标志物变化。结果显示,2003至2014年间克罗恩病相关住院率下降32.4%,住院手术率下降39.6%,急诊就诊率下降28.4%,而符合公共药物福利的患者中生物制剂使用率从2.2%升至18.8%。

要点

  • 克罗恩病相关住院率从154/1000降至104/1000,降幅32.4%。
  • 住院手术率从53/1000降至32/1000,降幅39.6%,以肠切除为主。
  • 生物制剂使用率从2.2%增至18.8%,住院与手术率同步下降。

核心结论

  • 研究期间安大略省克罗恩病患者的住院率、急诊就诊率和住院手术率显著下降,同时符合公共药物福利患者的生物制剂使用率大幅增加。

研究设计与样本

  • 基于人群的队列研究,使用加拿大安大略省行政数据,纳入2003年4月1日至2014年3月31日安大略省克罗恩病与结肠炎队列(OCCC)中45 235例患病患者。

主要发现

  • 克罗恩病相关住院率从2003年154/1000(95%CI [150, 159])降至2014年104/1000(95%CI [101, 107]),下降32.4%(P < .001)。
  • 住院手术率从53/1000(95%CI [50, 55])降至32/1000(95%CI [30, 34]),下降39.6%(P < .001),以肠切除为主。
  • 门诊手术率从8/1000(95%CI [7, 9])升至12/1000(95%CI [10, 13])(P < .001),主要与瘘管、肛周疾病及狭窄扩张/狭窄成形术相关。
  • 克罗恩病相关急诊就诊率从141/1000(95%CI [137, 146])降至101/1000(95%CI [99, 104]),下降28.4%(P < .001)。
  • 接受政府药物福利的患者中,英夫利西单抗或阿达木单抗联合使用率从2003年2.2%升至2014年18.8%。

临床怎么用

  • 在生物制剂使用增加的背景下,克罗恩病患者的住院和住院手术需求呈下降趋势,门诊手术需求相对增加。
  • 临床评估中可关注门诊手术(如瘘管、肛周疾病及狭窄扩张)的增加趋势,优化日间诊疗路径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lifetime risk of surgery in patients with Crohn's disease remains high. AIM: To assess population-level markers of Crohn's disease (CD) in the era of biological therapy. METHODS: Population-based cohort study using administrative data from Ontario, Canada including 45 235 prevalent patients in the Ontario Crohn's and Colitis Cohort (OCCC) from 1 April 2003 to 31 March 2014. RESULTS: CD-related hospitalisations declined 32.4% from 2003 to 2014 from 154/1000 (95% confidence interval (CI) [150, 159]) patients to 104/1000 (95% CI [101, 107]) (P < .001). There was a 39.6% decline in in-patient surgeries from 53/1000 (95% CI [50, 55]) to 32/1000 (95% CI [30, 34]) from 2003 to 2014 (P < .001). In-patient surgeries were mostly bowel resections. Out-patient surgeries increased from 8/1000 (95% CI [7, 9]) patients to 12/1000 (95% CI [10, 13]) (P < .001). Out-patient surgeries were largely related to fistulas and perianal disease and for stricture dilations/stricturoplasty. CD-related emergency department (ED) visits declined 28.4% from 141/1000 (95% CI [137, 146]) cases to 101/1000 (95% CI [99, 104]) from 2003 to 2014 (P < .001). Over the same time, patients receiving government drug benefits received infliximab or adalimumab at a combined rate of 2.2% in 2003 which increased to 18.8% of eligible patients by 2014. CONCLUSIONS: Rates of hospitalisations, ED visits and in-patient surgeries markedly declined in Ontario over the study period, while rates of biologic medication use increased markedly for those receiving public drug benefits.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rahman A, Jairath V, Feagan BG, et al. Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort. Aliment Pharmacol Ther. 2019. PMID: 31621934. doi:10.1111/apt.15511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。